{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:12:44Z","timestamp":1792811564912,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010607","name":"Universit\u00e0 degli Studi di Perugia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010607","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s40261-020-00982-8","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T05:05:46Z","timestamp":1607317546000},"page":"43-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8033-4945","authenticated-orcid":false,"given":"Michela","family":"Giustozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Mazzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Paciaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Vedovati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"issue":"9921","key":"982_CR1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0.","journal-title":"Lancet."},{"issue":"12","key":"982_CR2","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","volume":"124","author":"N van Es","year":"2014","unstructured":"van Es N, Coppens M, Schulman S, Middeldorp S, B\u00fcller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968\u201375. https:\/\/doi.org\/10.1182\/blood-2014-04-571232.","journal-title":"Blood"},{"key":"982_CR3","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/europace\/euq160","volume":"12","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Agladze V, Aliot E, Balabanski T, Blomstrom-Lundqvist C, Capucci A, Crijns H, Dahlof B, Folliguet T, Glikson M, Goethals M, Gulba DC, Ho SY, Klautz RJ, Kose S, McMurray J, Perrone Filardi P, Raatikainen P, Salvador MJ, Schalij MJ, Shpektor A, Sousa J, Stepinska J, Uuetoa H, Zamorano JL, Zupan I. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360\u2013420.","journal-title":"Europace"},{"key":"982_CR4","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3389\/fneur.2018.01067","volume":"9","author":"A Galgani","year":"2018","unstructured":"Galgani A, Palleria C, Iannone LF, De Sarro G, Giorgi FS, Maschio M, Russo E. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Front Neurol. 2018;9:1067.","journal-title":"Front Neurol."},{"issue":"1\u201302","key":"982_CR5","first-page":"9","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gr\u00fcnder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, M\u00f6ssner R, M\u00fcller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1\u201302):9\u201362.","journal-title":"Pharmacopsychiatry."},{"issue":"8","key":"982_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473\u201381.","journal-title":"Lancet Neurol."},{"key":"982_CR7","unstructured":"Cytochrome P-450 CYP3A4 Inducers. DrugBank. https:\/\/www.drugbank.ca\/categories\/DBCAT003896. Accessed 10 Oct 2015."},{"key":"982_CR8","unstructured":"P-glycoprotein inducers. DrugBank. https:\/\/www.drugbank.ca\/categories\/DBCAT002666. Accessed 6 Sep 2020."},{"issue":"9","key":"982_CR9","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.amjcard.2016.07.063","volume":"118","author":"CY Hsu","year":"2016","unstructured":"Hsu CY, Chen TH, Su YW, Chang CC, Chen MH, Leu HB, Huang PH, Chen JW, Lin SJ. Usefulness of the CHADS2 score for determining risk of seizure in patients with atrial fibrillation. Am J Cardiol. 2016;118(9):1340\u20134. https:\/\/doi.org\/10.1016\/j.amjcard.2016.07.063.","journal-title":"Am J Cardiol"},{"issue":"2","key":"982_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1474-4422(17)30404-0","volume":"17","author":"M Galovic","year":"2018","unstructured":"Galovic M, D\u00f6hler N, Erd\u00e9lyi-Canavese B, Felbecker A, Siebel P, Conrad J, Evers S, Winklehner M, von Oertzen TJ, Haring HP, Serafini A, Gregoraci G, Valente M, Janes F, Gigli GL, Keezer MR, Duncan JS, Sander JW, Koepp MJ, Tettenborn B. Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study. Lancet Neurol. 2018;17(2):143\u201352.","journal-title":"Lancet Neurol."},{"key":"982_CR11","doi-asserted-by":"crossref","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidb\u00fcchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330\u20131393.","DOI":"10.1093\/eurheartj\/ehy136"},{"key":"982_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejim.2016.06.022","volume":"33","author":"M Giustozzi","year":"2016","unstructured":"Giustozzi M, Vedovati MC, Verdecchia P, Pierpaoli L, Verso M, Conti S, Cianella F, Marchesini E, Filippucci E, Agnelli G, Becattini C. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life. Eur J Intern Med. 2016;33:42\u20136.","journal-title":"Eur J Intern Med"},{"key":"982_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijms HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263\u201372.","journal-title":"Chest"},{"key":"982_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093\u2013100.","journal-title":"Chest"},{"key":"982_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"982_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.clpt.2004.04.011","volume":"76","author":"T Giessmann","year":"2004","unstructured":"Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, Dazert P, Grube M, Schroeder E, Warzok R, Cascorbi I, Kroemer HK, Siegmund W. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther. 2004;76(3):192\u2013200.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"982_CR17","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1528-1167.2007.00924.x","volume":"48","author":"AH Andreasen","year":"2007","unstructured":"Andreasen AH, Br\u00f8sen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia. 2007;48(3):490\u20136.","journal-title":"Epilepsia."},{"issue":"1","key":"982_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/pgs.12.180","volume":"14","author":"YG Puranik","year":"2013","unstructured":"Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, Leppik IE, Lamba JK. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013;14(1):35\u201345.","journal-title":"Pharmacogenomics."},{"issue":"7","key":"982_CR19","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1111\/j.1476-5381.2009.00634.x","volume":"159","author":"X Jing","year":"2010","unstructured":"Jing X, Liu X, Wen T, Xie S, Yao D, Liu X, Wang G, Xie L. Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats. Br J Pharmacol. 2010;159(7):1511\u201322.","journal-title":"Br J Pharmacol"},{"issue":"1\u20132","key":"982_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eplepsyres.2010.12.013","volume":"94","author":"L Moerman","year":"2011","unstructured":"Moerman L, Wyffels L, Slaets D, Raedt R, Boon P, De Vos F. Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with (11)C-desmethylloperamide. Epilepsy Res. 2011;94(1\u20132):18\u201325.","journal-title":"Epilepsy Res"},{"issue":"2","key":"982_CR21","first-page":"250","volume":"27","author":"JM Nicolas","year":"1999","unstructured":"Nicolas JM, Collart P, Gerin B, Mather G, Trager W, Levy R, Roba J. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos. 1999;27(2):250\u20134.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"982_CR22","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1124\/dmd.106.014456","volume":"35","author":"L Cerveny","year":"2007","unstructured":"Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, Pavek P. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35(7):1032\u201341.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"982_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.0306-5251.2001.01474.x","volume":"52","author":"X Wen","year":"2001","unstructured":"Wen X, Wang JS, Kivist\u00f6 KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52(5):547\u201353.","journal-title":"Br J Clin Pharmacol"},{"key":"982_CR24","doi-asserted-by":"crossref","unstructured":"Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Bartels DB, Lip GYH; GLORIA-AF Investigators. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. Am Heart J. 2018;198:55\u201363.","DOI":"10.1016\/j.ahj.2017.08.018"},{"issue":"5","key":"982_CR25","doi-asserted-by":"crossref","first-page":"e002721","DOI":"10.1161\/JAHA.115.002721","volume":"5","author":"EC O\u2019Brien","year":"2016","unstructured":"O\u2019Brien EC, Kim S, Thomas L, Fonarow GC, Kowey PR, Mahaffey KW, Gersh BJ, Piccini JP, Peterson ED. Clinical characteristics, oral anticoagulation patterns, and outcomes of medicaid patients with atrial fibrillation: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF I) registry. J Am Heart Assoc. 2016;5(5):e002721.","journal-title":"J Am Heart Assoc."},{"issue":"6","key":"982_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.118.035012","volume":"139","author":"JP Bassand","year":"2019","unstructured":"Bassand JP, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK. Early risks of death, stroke\/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation. Circulation. 2019;139(6):787\u201398.","journal-title":"Circulation"},{"issue":"19","key":"982_CR27","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1093\/eurheartj\/ehy780","volume":"40","author":"FX Mathy","year":"2019","unstructured":"Mathy FX, Dohin E, Bonfitto F, Pelgrims B. Drug-drug interaction between levetiracetam and non-vitamin K antagonist anticoagulants. Eur Heart J. 2019;40(19):1571.","journal-title":"Eur Heart J"},{"issue":"1","key":"982_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.7326\/L19-0712","volume":"173","author":"F Paciullo","year":"2020","unstructured":"Paciullo F, Costa C, Gresele P. Rivaroxaban plasma levels and levetiracetam: a case report. Ann Intern Med. 2020;173(1):71\u20132.","journal-title":"Ann Intern Med"},{"issue":"12","key":"982_CR29","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s40263-019-00677-5","volume":"33","author":"A Perlman","year":"2019","unstructured":"Perlman A, Wanounou M, Goldstein R, Choshen Cohen L, Singer DE, Muszkat M. Ischemic and thrombotic events associated with concomitant Xa-inhibiting direct oral anticoagulants and antiepileptic drugs: analysis of the FDA adverse event reporting system (FAERS). CNS Drugs. 2019;33(12):1223\u20138.","journal-title":"CNS Drugs"},{"issue":"4","key":"982_CR30","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s11239-018-01804-7","volume":"47","author":"A Perlman","year":"2019","unstructured":"Perlman A, Hochberg-Klein S, Choshen Cohen L, Dagan G, Hirsh-Raccah B, Horwitz E, Aldouby-Bier G, Negev T, Matok I, Azoulay L, Kalish Y, Muszkat M. Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. J Thromb Thrombol. 2019;47(4):590\u20135.","journal-title":"J Thromb Thrombol"},{"key":"982_CR31","doi-asserted-by":"publisher","unstructured":"Wang CL, Wu VC, Chang KH, Tu HT, Kuo CF, Huang YT, Chu PH, Kuo CC, Chang SH. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin k antagonist oral anticoagulants and antiepileptic drugs. Eur Heart J Cardiovasc Pharmacother. 2019. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz035.","DOI":"10.1093\/ehjcvp\/pvz035"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-020-00982-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T18:22:32Z","timestamp":1670005352000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-020-00982-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["982"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00982-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,7]]},"assertion":[{"value":"24 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Perugia within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Michela Giustozzi, Matteo Mazzetti and Maria Cristina Vedovati have no conflict of interest to declare. Maurizio Paciaroni received honoraria as a member of the speaker bureau of Aspen, Sanofi-Aventis, Boehringer Ingelheim, Bayer, Bristol Meyer Squibb, Daiiki Sankyo and Pfizer. Giancarlo Agnelli received honoraria as a member of the speaker bureau of Bristol-Meyers-Squibb, Pfizer and Bayer. Cecilia Becattini received honoraria as a member of the speaker bureau of Bristol-Meyers-Squibb, Pfizer, Bayer and Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in this study were in accordance with the 1964 Helsinki declaration and its amendments. The study was approved by the local institutional review board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from patients, parents or caregivers.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Data that support the findings of this study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Michela Giustozzi contributed to the interpretation of data, drafting and critical revision of the manuscript and is the guarantor of the paper, taking responsibility for the integrity of the work as a whole, from inception to published article; Matteo Mazzetti, Maurizio Paciaroni, Giancarlo Agnelli, Cecilia Becattini and Maria Cristina Vedovati contributed to the conception and design of the study, to the statistical analyses, to the interpretation of data, drafting and critical revision of the manuscript.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}